Support options include support for spam and abuse victims, technical support for issues, legal support resources, counseling resources, and emergency support services.

ijpscr is committed to the long-term preservation of all published pharmaceutical research articles, ensuring permanent access to scholarly content for future generations of pharmaceutical researchers, practitioners, and policy makers. This commitment encompasses multiple preservation principles and comprehensive archiving strategies to maintain the integrity and accessibility of the journal's scholarly record.

ijpscr employs a comprehensive archiving strategy utilizing multiple preservation networks. Multiple archive systems include a primary archive maintained by the journal, secondary archives for backup purposes, institutional archives through university partnerships, national library archives for broad preservation, and commercial archives for additional security. Preservation networks include LOCKSS (Lots of Copies Keep Stuff Safe) for decentralized preservation, CLOCKSS (Controlled Lots of Copies Keep Stuff Safe) for managed digital preservation, Portico for digital preservation services, and Internet Archive for public digital archiving.

The journal focuses on preserving pharmaceutical-relevant research content. Pharmaceutical Sciences research includes analytical methods and findings that support data-driven decision making. Market research encompasses market analysis and consumer behavior studies that inform pharmaceutical strategy. Financial analysis research includes financial modeling and investment studies that guide pharmaceutical decisions. Clinical Research studies research includes organizational behavior and leadership research relevant to pharmaceutical practice.

ijpscr publishes cutting-edge research across three interconnected domains that drive modern pharmaceutical innovation and strategy. The journal serves as a premier platform for scholarly work that bridges theoretical insights with practical pharmaceutical applications in the digital age.

Original research articles present comprehensive studies that make significant contributions to pharmaceutical knowledge. These articles should be 6,000-10,000 words in length and focus on original pharmaceutical research findings with rigorous research methodology. The contribution should advance pharmaceutical knowledge significantly and demonstrate practical pharmaceutical applications that can benefit practitioners and researchers alike.

The Results section presents findings with statistical analysis results, tables and figures, and supplementary results. The Discussion section interprets results, compares with existing literature, discusses theoretical and practical implications, and addresses limitations and future research. The Conclusion section summarizes research, highlights key contributions, discusses practical applications, and suggests future research directions.

A conflict of interest arises when personal, financial, professional, or other relationships could reasonably be perceived to influence the objectivity, integrity, or perceived integrity of pharmaceutical research, editorial decisions, or publication processes. ijpscr is committed to identifying and managing such conflicts to maintain the highest standards of academic and professional transparency.

Financial interests encompass several areas, including current or recent employment relationships, consulting arrangements, and contracts. Authors must also disclose stock or equity holdings, patent applications or royalties, and payments for lectures, presentations, or services such as honoraria. All sources and amounts of research funding must be clearly stated. Professional relationships involve advisory roles, leadership positions in professional societies, and collaborative research initiatives. Mentorship relationships, such as student-mentor connections, and competitive pharmaceutical relationships must also be disclosed. Personal relationships that require disclosure include family member connections, close personal ties, romantic or intimate relationships, and significant friendship or community social relationships that could influence professional judgment.

The Editor-in-Chief carries specific disclosure obligations to lead by example in transparency. These include the disclosure of any personal conflicts of interest and institutional conflicts that could arise from their primary affiliations. Financial conflicts must be declared, along with professional conflicts related to their leadership roles in other organizations. Additionally, any clinical research conflicts that could influence the overall direction or specific decisions of the journal must be disclosed.

Upon acceptance for publication, authors transfer copyright to GTS Press, the publisher of ijpscr. This transfer grants the publisher exclusive rights to publish, reproduce, distribute, and create derivative works from the submitted manuscript. The copyright transfer ensures that the publisher can effectively manage and protect the published work while maintaining appropriate quality control and dissemination strategies.

Under the copyright transfer agreement, authors retain significant rights to their work: the right to use their work in teaching, training, and presentations; the right to include their work in theses and dissertations; the right to share pre-print versions on personal or institutional repositories; and the right to use their work in future research with proper citation. These retained rights ensure that authors can continue to benefit from their scholarly contributions.

All articles published in ijpscr are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows anyone to share, adapt, and build upon the published work for any purpose, provided that appropriate attribution is given to the original authors and the journal. The CC BY 4.0 license maximizes the impact and reach of published research while protecting authors' moral rights.

A corrigendum corrects errors made by the authors that affect the article but do not invalidate the overall conclusions. Corrigendum criteria include errors made by authors, data calculation or analysis errors, methodology description errors, result interpretation errors, and citation and reference errors.

Impact evaluation considers impact on research findings, impact on practical applications, impact on academic community, impact on pharmaceutical community, and impact on future research.

A Digital Object Identifier (DOI) is a unique alphanumeric string assigned to a digital object, such as a journal article, to provide a persistent link to its location on the internet.

The registration agency is Crossref, providing Crossref registration, Crossref metadata standards, DOI resolution services, and Crossref support services.

Support services include DOI resolution support, metadata support, registration support, quality support, and general support.

ijpscr is committed to transparency and reproducibility in pharmaceutical research. We encourage authors to make their research data available to support scholarly work and enable pharmaceutical applications. The journal's data sharing principles are rooted in transparency, where open sharing of research data is encouraged whenever possible. This commitment to reproducibility enables the independent verification of research findings, while also supporting practical pharmaceutical applications that can benefit from underlying datasets. Furthermore, the journal ensures ethical compliance by maintaining high legal and ethical standards, and prioritizes privacy protection to safeguard sensitive pharmaceutical and personal information.

ijpscr recognizes that certain data cannot be shared due to various constraints. Permitted exemptions include confidential pharmaceutical data that contains proprietary information and personal data that involves sensitive individual information. Legal restrictions and ethical constraints may also prevent data sharing in certain jurisdictions or research contexts. Additionally, information that is commercially sensitive and could harm the competitive position of organizations or individuals is exempt from mandatory sharing requirements.

The journal recognizes several categories of quantitative pharmaceutical data that may be shared to support research integrity. Financial data encompasses financial statements, market data, and economic indicators that provide context for pharmaceutical performance and trends. Operational data includes pharmaceutical operations metrics that help understand organizational efficiency and process improvements. Market data consists of market research and survey data that supports broader pharmaceutical understanding. Performance data includes pharmaceutical performance indicators that measure effectiveness of strategies and initiatives. Economic data encompasses economic indicators and indices that provide macro-level context for pharmaceutical research.

The content published in ijpscr reflects the research findings and opinions of the authors. Published material represents the authors' own views and methodologies. Research findings expressed in articles are the authors' interpretations and do not represent the journal's position. Methodology approaches are the responsibility of the authors and may not represent the journal's preferred methods. Conclusions drawn from research are the authors' interpretations and may not represent broader consensus in the field.

Information reliability in published research varies by multiple factors. Data accuracy is the responsibility of the authors, who must ensure that all information is correct and properly validated. Statistical analysis validity depends on research design and sample characteristics. Pharmaceutical applications may require professional validation before implementation. Market conditions can change rapidly, affecting the relevance of research findings over time.

The journal assumes no liability for content inaccuracies or their consequences. Published material is provided 'as is' without liability for errors or omissions. No liability is assumed for financial losses resulting from pharmaceutical decisions based on published content. The journal is not responsible for professional advice or pharmaceutical decisions made by readers based on published research.

Process standards include timely review and publication, clear communication with authors, consistent editorial processes, transparent editorial decisions, and professional editorial conduct.

The International Journal of Pharmaceutical Sciences and Clinical Research (IJPSCR) is committed to maintaining the highest standards of editorial excellence and ethical conduct in pharmaceutical and clinical research publishing. Our editorial policy establishes comprehensive guidelines for all aspects of the publication process, ensuring that all published research meets rigorous academic standards while maintaining practical relevance to pharmaceutical and clinical challenges. This policy serves as a foundational document that guides our editorial board, reviewers, authors, and readers through the publication process while upholding the principles of transparency, fairness, and scholarly integrity.

Associate editors are appointed based on their expertise in specific areas of pharmaceutical sciences and clinical research, ensuring that each manuscript receives appropriate specialized review. Associate editors are responsible for overseeing the peer review process, making initial editorial decisions, and managing communications with authors and reviewers. They work under the guidance of the Editor-in-Chief to maintain high standards of editorial quality and consistency in decision-making.

The editorial board comprises distinguished experts from various fields of pharmaceutical sciences and clinical research who provide strategic guidance and oversight for the journal. Board members participate in policy development, conflict resolution, and ensuring that the journal maintains its commitment to excellence and ethical publishing practices. The board meets regularly to review and update editorial policies in response to evolving publishing standards and emerging challenges in pharmaceutical and clinical research.

ijpscr is committed to comprehensive indexing in major pharmaceutical and academic databases to ensure maximum visibility, accessibility, and impact of published pharmaceutical research.

The International Journal of Pharmaceutical Sciences and Clinical Research (ijpscr) publishes all articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing framework is fundamental to the journal's mission of ensuring widespread accessibility and impact for pharmaceutical research.

Under the CC BY 4.0 license, users are granted broad rights to engage with published materials. They are free to share the content by copying and redistributing it in any medium or format. The license also permits users to adapt the work, allowing for remixing, transforming, and building upon the material for any purpose. Significantly, Our scope encompasses commercial purposes, which is particularly relevant for pharmaceutical practitioners, consultants, and industry analysts. These rights are granted without additional restrictions, provided the required conditions are met.

The sharing rights under the journal's license encompass several allowed actions that facilitate research dissemination. These include the ability to make unlimited copies of articles and distribute them through any medium. Electronic transmission and sharing are encouraged, as are public displays and performances of the research findings. Furthermore, the license supports long-term archiving and preservation of articles in institutional or subject-specific repositories.

ijpscr upholds fundamental principles that guide research integrity and ethical conduct. Honesty is essential, requiring honest reporting of research, procedures, data, and outcomes to ensure the credibility and reliability of published work. Transparency is emphasized through transparent reporting of methods, data, and results, allowing readers to evaluate research findings and reproduce studies when necessary. Accountability is enforced through accountability for research conduct and reporting, ensuring that researchers take responsibility for their work and its implications. Professionalism is maintained through professional conduct in all aspects of research, from initial design through publication and dissemination. Respect is demonstrated through respect for research participants, colleagues, and the research community, fostering an environment of collaboration and mutual support in advancing pharmaceutical knowledge.

ijpscr applies escalating consequences for plagiarism violations based on severity and frequency. A First Offense results in a major revision request and ethics education to help authors understand and correct their mistakes. A Second Offense leads to rejection and a 3-year publication ban to prevent repeated violations. Severe Cases involving extensive plagiarism result in immediate rejection and permanent publication ban. For Published Work with proven plagiarism, retraction and institutional notification are required to maintain the scholarly record. Legal Action may be pursued for copyright infringement where applicable, especially in cases of commercial plagiarism. Professional Sanctions include professional association notification to maintain ethical standards across the academic community.

Data falsification manifests in several deceptive practices that authors must strictly avoid. Fabrication involves creating non-existent pharmaceutical data or results, representing a complete invention of research findings. Manipulation includes altering pharmaceutical data to fit specific hypotheses or desired outcomes, distorting the truth to support a preferred narrative. Selective Reporting involves omitting unfavorable pharmaceutical outcomes or data points that contradict the researcher's conclusions, leading to a biased presentation of results. Misrepresentation includes distorting pharmaceutical research findings through misleading interpretations or presentations. Methodological Fraud involves misrepresenting research methods to make them appear more robust or appropriate than they actually were. Statistical Fraud includes manipulating statistical analyses to achieve significant results or hide variability. Data Mining Fraud involves misrepresenting data mining results through inappropriate techniques or biased selection of patterns.

The International Journal of Pharmaceutical Sciences and Clinical Research (ijpscr) is committed to open access publishing that ensures immediate, free access to all published research for readers worldwide. Our open access policy establishes comprehensive guidelines for the dissemination of scholarly work while maintaining the highest standards of academic quality and sustainable publishing practices in Pharmaceutical Sciences and Clinical Research research. This policy serves to maximize the impact and reach of published research, promote global knowledge sharing, and support the advancement of Pharmaceutical Sciences and Clinical Research scholarship across institutional and geographic boundaries.

All articles published in ijpscr are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows readers to share, adapt, and build upon published work for both commercial and non-commercial purposes, provided that appropriate attribution is given to the original authors and the journal. The CC BY 4.0 license ensures maximum dissemination while protecting authors' rights and ensuring proper credit for scholarly contributions.

Upon publication, all articles are immediately available online without any access barriers or embargoes. Readers can access full-text content immediately upon publication, ensuring rapid dissemination of research findings. This immediate access model supports the fast-paced nature of Pharmaceutical Sciences and Clinical Research research where timely information is critical for practice and policy development.

The International Journal of Pharmaceutical Sciences and Clinical Research (ijpscr) is committed to maintaining rigorous peer review standards that ensure the quality, integrity, and scholarly contribution of all published research. Our peer review policy establishes comprehensive guidelines for the evaluation of manuscripts, ensuring that all published content meets the highest standards of academic excellence while maintaining practical relevance to contemporary Pharmaceutical Sciences and Clinical Research challenges. This policy serves as a foundational framework that guides our reviewers, editorial board, and authors through the peer review process while upholding the principles of objectivity, fairness, and constructive evaluation.

Reviewers are selected based on their demonstrated expertise in specific areas of Pharmaceutical Sciences and Clinical Research. The journal maintains a comprehensive database of qualified reviewers with proven track records of scholarly contributions, research experience, and practical applications in their respective fields. Reviewers must hold advanced degrees in relevant disciplines and have recent publications in peer-reviewed journals, ensuring that each manuscript receives evaluation from individuals with appropriate subject matter knowledge and methodological understanding.

Reviewers are required to have substantial experience in pharmaceutical research, either through academic positions, industry practice, or consulting roles. This practical experience ensures that reviewers can evaluate manuscripts not only on their academic merit but also on their practical relevance and applicability to real-world pharmaceutical settings. The journal values reviewers who can bridge theoretical knowledge with practical pharmaceutical applications.

Plagiarism is defined as the use of another person's ideas, words, or work without proper attribution or permission. Our scope encompasses direct copying, paraphrasing without citation, submitting previously published work as original, and self-plagiarism where authors reuse their own previous work without appropriate disclosure. The journal recognizes various forms of plagiarism including verbatim copying, mosaic plagiarism, paraphrasing plagiarism, and source-based plagiarism.

The journal considers the following forms of academic misconduct: plagiarism and text recycling; data fabrication and falsification; duplicate publication; authorship misconduct including gift authorship and ghost authorship; citation manipulation; and breach of confidentiality. Each form of misconduct undermines the integrity of scholarly communication and is subject to appropriate action.

All submitted manuscripts undergo comprehensive plagiarism screening using advanced detection software and manual review by editorial staff. The detection process includes: similarity analysis against extensive databases of academic literature; cross-checking with previously published works; verification of proper citation practices; and assessment of originality in data presentation and analysis. Manuscripts with similarity scores above 10% trigger detailed review and potential rejection.

ijpscr is committed to protecting the privacy and personal data of all users, including authors, reviewers, editors, readers, and website visitors, in compliance with international privacy regulations and pharmaceutical ethics standards.

ijpscr is committed to the highest standards of publication ethics in pharmaceutical research, following comprehensive guidelines from leading international organizations. The Committee on Publication Ethics (COPE) provides best practices for publication ethics and handling of misconduct, ensuring the journal maintains ethical integrity in all editorial processes. The International Committee of Medical Journal Editors (ICMJE) establishes standards for authorship, peer review, and scientific conduct that the journal follows to maintain academic quality. The World Association of Medical Editors (WAME) provides guidance on editorial independence, peer review, and publication ethics that shape the journal's ethical framework. The Council of Science Editors (CSE) guidelines ensure high standards in scientific communication and editorial practices. The Open Access Scholarly Publishers Association (OASPA) provides standards for open access publishing that the journal follows to ensure ethical and transparent dissemination of research.**

ijpscr is committed to maintaining the highest standards of research integrity through comprehensive ethical principles that guide all aspects of research and publication. Honesty is fundamental, requiring honest reporting of research, procedures, data, and outcomes to ensure the credibility and reliability of published work. Transparency is emphasized through transparent reporting of methods, data, and results, allowing readers to evaluate research findings and reproduce studies when necessary. Accountability is enforced through accountability for research conduct and reporting, ensuring that researchers take responsibility for their work and its implications. Professionalism is maintained through professional conduct in all aspects of research, from initial design through publication and dissemination. Respect is demonstrated through respect for research participants, colleagues, and the research community, fostering an environment of collaboration and mutual support in advancing pharmaceutical knowledge.

Pharmaceutical Regulations:

The journal operates on a quarterly publication schedule with specific timing for both online and print distribution. The primary frequency is quarterly publication with 4 issues annually, published in March, June, September, and December. Online publication occurs immediately upon acceptance, while print publication follows a quarterly compilation schedule.

The publication model employs a hybrid approach including immediate online publication, quarterly issue compilation, quarterly print edition, continuous publication model, and annual volume structure.

Volume progression shows the journal's history from Volume 1 in 2018 through Volume 9 in 2026 as the current volume.

Articles may be retracted due to serious research misconduct including: data fabrication or falsification; plagiarism or text recycling; deliberate manipulation of results or conclusions; and ethical violations in research conduct. These serious breaches of academic integrity undermine the credibility of the scholarly record and require prompt action to maintain research standards.

Articles may be retracted due to honest errors that significantly affect the research findings: methodological errors that invalidate conclusions; calculation errors that change results substantially; data analysis mistakes that lead to incorrect interpretations; and experimental design flaws that compromise the entire study. Honest errors, while serious, are distinguished from misconduct and are handled with understanding while maintaining research integrity.

Retraction may be necessary due to violations of publication ethics: failure to obtain proper ethical approvals; inadequate informed consent procedures; breach of participant confidentiality; and failure to disclose significant conflicts of interest. These violations undermine trust in the research process and may necessitate article removal.

A special issue is a collection of articles focused on a specific theme, topic, or research area within Pharmaceutical Sciences and Clinical Research, edited by guest editors with expertise in the subject area.

ijpscr welcomes submissions of original research, case studies, review articles, and technical reports that contribute to the advancement of Pharmaceutical Sciences, clinical research practices, and Medical Research research. The journal accepts several manuscript types including original empirical research articles of 6,000-10,000 words, pharmaceutical case analyses of 4,000-8,000 words, comprehensive literature reviews of 8,000-12,000 words, and methodological papers of 5,000-9,000 words.

The journal welcomes submissions from diverse author backgrounds including academic faculty, researchers, and graduate students, pharmaceutical practitioners, consultants, and analysts, policy makers and government researchers, authors from any country, and multi-institutional collaborative teams.

Authors may need to obtain various institutional approvals including Institutional Review Board approval for human subject research, institutional ethics committee approval, data governance approval, funding agency clearance, and institutional publication clearance.

Email submission is permitted only for technical issues with the online system, system problem submissions, special circumstances, with prior editorial approval required and complete documentation required.

Support options include technical support, editorial support, author support, frequently asked questions, and direct contact options.

IJPSCR publishes cutting-edge research across three interconnected domains: Pharmaceutical Sciences, Clinical Research, and Medical Research. The journal welcomes submissions of original research articles, pharmaceutical case studies, comprehensive literature reviews, and methodological papers that contribute to the advancement of pharmaceutical sciences and clinical research.

All submissions must represent original work that has not been published previously and is not under consideration for publication elsewhere. Publication requires approval from all co-authors and responsible authorities at the institute where the work was carried out.

Submission of a manuscript implies that the work described has not been published before, is not under consideration for publication anywhere else, and its publication has been approved by all co-authors and responsible authorities at the institute where the work was carried out.

Manuscript withdrawal refers to the voluntary removal of a submitted manuscript from the publication process by the author(s) at any stage before final publication.

Editorial assessment considers review completion status, editorial resource utilization, editorial time investment, manuscript quality assessment, and future publication consideration.